In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Proton pump inhibitor (PPI)'
Please login to view adverse reactions.
Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
Angioedema (formerly named angioneurotic edema)
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2012): Chularojanamontri L+, J Drugs Dermatol 11(10), e43-7
DRESS syndrome (Drug-induced hypersensitivity syndrome)
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
- (2016): Otani IM+, Curr Allergy Asthma Rep 16(3), 17 [REVIEW]
Lichenoid eruption / lichenoid reaction
- (2000): Bong JL+, BMJ 320(7230), 283
Lupus erythematosus (subacute cutaneous lupus erythematosus (SCLE))
- (2017): Laurinaviciene R+, Eur J Dermatol 27(1), 28
- (2016): Aggarwal N, Drugs Real World Outcomes 3(2), 145
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557 (severe) [REVIEW]
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
Toxic epidermal necrolysis (Lyell's syndrome)
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
Vasculitis (angiitis) / cutaneous vasculitis (angiitis)
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
- (2019): Chrysant SG, Expert Rev Cardiovasc Ther May, Epub ahead of print [REVIEW] (passim)
Cardiac disorder / cardiac dysfunction
Cardiac disorder / cardiac dysfunction
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557-570 [REVIEW]
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557 [REVIEW]
- (2025): Wang H+, Cardiovasc Toxicol May, Online ahead of print (with osimertinib) (with underlying comorbidities) (pharmacovigilance / pharmacoepidemiology)
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- Negative findings
- (2023): Abukhalil AD+, Patient Prefer Adherence 17, 749-759 (with clopidogrel; no significant increase in cardiovascular events was observed in patients receiving concomitant clopidogrel and proton pump inhibitor therapy.)
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557 [REVIEW]
- (2019): Chrysant SG, Expert Rev Cardiovasc Ther May, Epub ahead of print [REVIEW] (passim)
- (2024): Decros A+, BMJ Open 14(10), e081911 (association) (pharmacovigilance / pharmacoepidemiology)
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557 [REVIEW]
- (2015): Cohen S+, Br J Clin Pharmacol 80(2), 200 [REVIEW]
Stroke / cerebrovascular accident
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557 [REVIEW]
- (2019): Chrysant SG, Expert Rev Cardiovasc Ther May, Epub ahead of print [REVIEW]
- (2019): Chrysant SG+, Expert Opin Drug Saf Dec, Epub ahead of print [REVIEW]
- (2016): William JH+, World J Nephrol 5(2), 152 [REVIEW]
- (2014): Carter GT+, Phys Med Rehabil Clin N Am 25(2), 457
- (2014): Park CH+, PLoS One 9(11), e112558 [REVIEW]
- (2013): Wilhelm SM+, Expert Rev Clin Pharmacol 6(4), 443 [REVIEW]
- (2022): Swarnakari KM+, Cureus 14(11), e31672 [REVIEW]
- (2015): Cohen S+, Br J Clin Pharmacol 80(2), 200 [REVIEW]
- (2015): Cohen S+, Br J Clin Pharmacol 80(2), 200 [REVIEW]
Gastric adenocarcinoma / gastric cancer
- (2021): Salvo EM+, Aliment Pharmacol Ther Jun, Online ahead of print [REVIEW] (statistical association)
Gastrointestinal adverse reaction
- (2021): Salvo EM+, Aliment Pharmacol Ther Jun, Online ahead of print [REVIEW] (statistical association)
Gut microbiome / gut microbiota / gastrointestinal microbiota changes / disturbance
- (2024): Fossmark R+, Microorganisms 12(6), 1110 [REVIEW]
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2024): Wang L+, Expert Opin Drug Saf Oct, Online ahead of print (23 cases) [REVIEW]
- (2015): Cohen S+, Br J Clin Pharmacol 80(2), 200 [REVIEW]
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
- (2014): Shuman MD+, J Psychiatr Pract 20(1), 50 (with clozapine)
Pancytopenia (includes bicytopenia)
- (2018): Yu Z+, Drug Saf Case Rep 5(1), 28 (1 case / male)
Thrombocytopenia / platelets decreased
- (2015): Binnetoglu E+, Platelets 26(1), 10
- (2013): Wilhelm SM+, Expert Rev Clin Pharmacol 6(4), 443 [REVIEW]
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557 [REVIEW]
- (2021): Salvo EM+, Aliment Pharmacol Ther Jun, Online ahead of print [REVIEW] (statistical association)
- (2016): Abramowitz J+, Otolaryngol Head Neck Surg 155(4), 547 [REVIEW]
- (2013): Wilhelm SM+, Expert Rev Clin Pharmacol 6(4), 443 [REVIEW]
Myalgia/Myositis/Myopathy/Myotoxicity
- (2017): Colmenares EW+, Ann Pharmacother 51(1), 66 [REVIEW]
- (2013): Zofkova I, Vnitr Lek (Czech) 59(1), 59 [REVIEW]
- (2013): Wilhelm SM+, Expert Rev Clin Pharmacol 6(4), 443 [REVIEW]
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
- (2022): Wei X+, Drug Saf Jun, Online ahead of print [REVIEW]
- (2021): Klatte DCF+, Ned Tijdschr Geneeskd (Dutch) 165, D5534 [REVIEW]
- (2021): Salvo EM+, Aliment Pharmacol Ther Jun, Online ahead of print [REVIEW] (statistical association)
- (2013): Wilhelm SM+, Expert Rev Clin Pharmacol 6(4), 443 [REVIEW]
- (2012): Chang YS, Curr Opin Allergy Clin Immunol 12(4), 348 [REVIEW]
- (2016): Abramowitz J+, Otolaryngol Head Neck Surg 155(4), 547 [REVIEW]
Adverse effects / adverse reactions
- (2025): King E+, Cochrane Database Syst Rev 3, CD015127 [REVIEW]
- (2024): Alla D+, Glob Pediatr Health Apr (e-Collection) [REVIEW]
- (2024): Bhatnagar MS+, Cureus 16(1), e52773 [REVIEW]
- (2022): Chinzon D+, Arq Gastroenterol 59(2), 219-225 [REVIEW]
- (2022): Dipasquale V+, Front Pharmacol Feb (e-Collection) [REVIEW]
- (2022): Tyron JM+, Ugeskr Laeger (Danish) 184(15), V08210634 [REVIEW]
- (2020): Savarino V+, Dig Liver Dis Jun, Online ahead of print [REVIEW]
- (2017): Eusebi LH+, J Gastroenterol Hepatol 32(7), 1295 [REVIEW]
- (2017): Schnoll-Sussman F+, Curr Treat Options Gastroenterol 15(1), 1 [REVIEW]
- (2016): de la Coba Ortiz C+, Rev Esp Enferm Dig 108(4), 207 [REVIEW]
- (2021): Salvo EM+, Aliment Pharmacol Ther Jun, Online ahead of print [REVIEW] (statistical association)
- (2016): Abramowitz J+, Otolaryngol Head Neck Surg 155(4), 547 [REVIEW]
- (2018): Forgerini M+, Sao Paulo Med J 136(6), 557-570 [REVIEW]
